Shared on29 Jul 25Fair value Increased 13%
Verona Pharma's consensus price target was revised upward to reflect Merck’s $10B acquisition offer, anchoring fair value near the deal price due to high deal certainty and limited expectation of competing bids, with the updated analyst target now at $106.22 per share. Analyst Commentary Price targets were adjusted to $107 to reflect the announced $10B Merck acquisition, which set a definitive takeout value per share.